Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cincor Pharma Inc (CINC)

Cincor Pharma Inc (CINC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,271,782
  • Shares Outstanding, K 43,764
  • Annual Sales, $ 0 K
  • Annual Income, $ -50,370 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.11
Trade CINC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.57
  • Most Recent Earnings $-0.51 on 11/03/22
  • Latest Earnings Date 03/28/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.55
  • Number of Estimates 5
  • High Estimate -0.49
  • Low Estimate -0.57
  • Prior Year -15.71
  • Growth Rate Est. (year over year) +96.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.65 +1.43%
on 01/24/23
29.68 -2.09%
on 02/14/23
+0.23 (+0.80%)
since 01/23/23
3-Month
10.53 +175.97%
on 12/19/22
29.68 -2.09%
on 02/14/23
+3.43 (+13.38%)
since 11/23/22
52-Week
10.53 +175.97%
on 12/19/22
43.15 -32.65%
on 08/08/22
+3.91 (+15.55%)
since 02/23/22

Most Recent Stories

More News
SHAREHOLDER ALERT: Weiss Law Reminds ARGO, OSH, CINC, and DCT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

ARGO : 29.99 (-0.03%)
OSH : 39.00 (+0.08%)
CINC : 29.06 (-0.48%)
DCT : 18.99 (unch)
There's a Lot to Love About Mineralys' Valentine's Day IPO

MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million

MLYS : 11.04 (-2.82%)
AZN : 75.03 (+5.38%)
CINC : 29.06 (-0.48%)
GPCR : 38.98 (+7.00%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CINC, DCT, ANGN, CEMI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CINC : 29.06 (-0.48%)
DCT : 18.99 (unch)
ANGN : 10.0000 (+2.04%)
CEMI : 0.4550 (+0.22%)
SHAREHOLDER ALERT: Weiss Law Reminds CINC, DCT, PAYA, and DCP Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

CINC : 29.06 (-0.48%)
DCT : 18.99 (unch)
PAYA : 9.74 (+0.10%)
DCP : 41.69 (+0.07%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TCFC, TIG, CINC, DCT

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TCFC : 27.09 (-1.56%)
TIG : 6.16 (+0.16%)
CINC : 29.06 (-0.48%)
DCT : 18.99 (unch)
SHAREHOLDER ALERT: Weiss Law Reminds CINC, DCT, PAYA, and DCP Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

CINC : 29.06 (-0.48%)
DCT : 18.99 (unch)
PAYA : 9.74 (+0.10%)
DCP : 41.69 (+0.07%)
These 2 Healthcare Stocks Have Doubled in 2023

Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.

AUPH : 4.87 (-3.18%)
SHC : 11.32 (+0.44%)
CINC : 29.06 (-0.48%)
AZN : 75.03 (+5.38%)
CVNA : 77.50 (+2.85%)
MARA : 19.01 (-0.42%)
CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CinCor Pharma, Inc. (NasdaqGM: CINC) to AstraZeneca....

CINC : 29.06 (-0.48%)
SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

LPTX : 3.17 (-3.65%)
CNCE : 8.37 (+0.12%)
ALBO : 44.15 (-0.23%)
CINC : 29.06 (-0.48%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AQUA, CINC, ALBO, PAYA, GMGI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AQUA : 49.88 (+0.95%)
CINC : 29.06 (-0.48%)
ALBO : 44.15 (-0.23%)
PAYA : 9.74 (+0.10%)
GMGI : 4.11 (+8.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CinCor Pharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor Pharma Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 29.60
2nd Resistance Point 29.47
1st Resistance Point 29.27
Last Price 29.06
1st Support Level 28.94
2nd Support Level 28.81
3rd Support Level 28.61

See More

52-Week High 43.15
Fibonacci 61.8% 30.69
Last Price 29.06
Fibonacci 50% 26.84
Fibonacci 38.2% 22.99
52-Week Low 10.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar